33 results
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
1 Aug 22
HUTCHMED Reports 2022 Interim Results and Provides Business Updates
7:33am
the NDA for surufatinib for the treatment of pNETs and epNETs. FDA determined that the current data package, based on two positive Phase III trials … to any safety issues with surufatinib.
We also submitted an EMA MAA for surufatinib using the same data package, which was validated and accepted
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
2 May 22
Current report (foreign)
6:57am
determined that the current data package, based on two positive Phase III trials in China and one bridging study in the United States (U.S.), does
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
3 Mar 22
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
9:00am
results from a 34-patient, registration-enabling bridging study in Japan to complement the registration data package submitted to the U.S. FDA and the EMA
6-K
EX-99.1
l1eibrx wtsm
20 Sep 21
Current report (foreign)
6:27am
6-K
EX-99.1
wttv1k6yu
16 Jul 21
Current report (foreign)
6:33am
6-K
EX-99.1
oje9x91pzkm r3
2 Jul 21
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
7:14am
424B5
b3ax yx0rp
24 Jun 21
Prospectus supplement for primary offering
8:42am
6-K
EX-1.2
4d0 lcpnxo
24 Jun 21
Current report (foreign)
7:33am
6-K
EX-1.1
15k1lripr3o2h818hmp2
24 Jun 21
Current report (foreign)
7:33am
424B5
b0ltwhh lb
21 Jun 21
Prospectus supplement for primary offering
7:26am
6-K
572wiqea
21 Jun 21
HUTCHMED (China) Limited Supplemental and Updated Disclosures
6:27am
6-K
EX-99.1
cs6 xxxke22
21 Jun 21
HUTCHMED (China) Limited Supplemental and Updated Disclosures
6:27am
6-K
EX-99.2
y3mb7147
4 May 21
Current report (foreign)
6:35am
6-K
EX-99.1
gcdikfir6e llg
29 Dec 20
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
6:45am